Skip to main content
padlock icon - secure page this page is secure

Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy

Buy Article:

$68.00 + tax (Refund Policy)

ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 1-2 desferrioxamine; 2-fluoropropionic acid (FPA); 4-fluorobenzoic acid (FBA); ADC; CuAAC; Epidermal Growth Factor Receptor; HER2; Herceptin; Imaging technology; N-succinimidyl 3-iodobenzoate; N-succinimidyl 4-fluorobenzoate; PET; SFB; SIB; THIOMAB; Zevalin; antibody-drug conjugates; cetuximab, panitumumab; copper-I catalyzed 1,3- dipolar cycloaddition; gefitinib, erlotinib; hEGF; hydrazinonicotinic acid; immunoPET; monoclonal antibodies; positron emission tomography; radiolabeling; receptor targeted therapy; single photon computed tomography; trastuzumab

Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • The aim of Current Drug Delivery is to publish peer-reviewed articles, short communications, short and in-depth reviews in the rapidly developing field of drug delivery. Modern drug research aims to build in delivery properties of a drug at the design phase, however in many cases this ideal cannot be met and the development of delivery systems becomes as important as the development as the drugs themselves.

    The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.

    The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more